Medrx Co

Medrx Co Days Payable Outstanding

The Days Payable Outstanding (DPO) of Medrx Co (4586.T) as of Nov 19, 2026 is 471.41. In the previous year, Days Payable Outstanding (DPO) was 542.94 — a change of -13.17% (lower).

Days Payable Outstanding

471.41

YoY

-13.17%

Last updated:

Days Payable Outstanding (DPO) of Medrx Co is 2021 471.41 . Days Payable Outstanding (DPO) of Medrx Co was 2020 542.94 . It decreases by -13.17% lower compared to the previous year.

The Medrx Co Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2014
2.37 JPY
Jan 1, 2015
3.98 JPY
Jan 1, 2016
0.61 JPY
Jan 1, 2018
0.50 JPY
Jan 1, 2019
598.65 JPY
Jan 1, 2020
542.94 JPY
Jan 1, 2021
471.41 JPY
The Medrx Co Days Payable Outstanding history
YEARDays Payable OutstandingYoY
471.41-13.17%
542.94-9.31%
598.65+119,668.78%
0.50-17.41%
0.61-84.79%
3.98+67.53%
2.37—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Days Payable Outstanding (DPO) of Medrx Co is 471.41 in 2021.

Days Payable Outstanding (DPO) of Medrx Co changed from 542.94 to 471.41, representing a -13.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Medrx Co since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Medrx Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Medrx Co

All Key Metrics — Medrx Co